| Literature DB >> 28916897 |
David Riedl1, Johannes M Giesinger2, Lisa M Wintner1, Fanny L Loth1, Gerhard Rumpold1, Richard Greil3, Alain Nickels4, Thomas Licht4, Bernhard Holzner5.
Abstract
BACKGROUND: With the growing number of cancer survivors worldwide the need for high quality cancer rehabilitation after primary treatment is steadily increasing. The aim of the present study was to investigate change of psychological distress and health-related quality of life (HRQOL) during multidisciplinary inpatient cancer rehabilitation in a large sample of cancer survivors suffering from different cancer entities.Entities:
Keywords: Cancer; Health-related quality of life (HRQOL); Inpatient; Psychological distress; Rehabilitation
Mesh:
Year: 2017 PMID: 28916897 PMCID: PMC5630652 DOI: 10.1007/s00508-017-1266-z
Source DB: PubMed Journal: Wien Klin Wochenschr ISSN: 0043-5325 Impact factor: 1.704
Applied treatment interventions
| Treatment | Treatment frequency per patient | |||
|---|---|---|---|---|
|
| (%) |
|
| |
| Physiotherapy/physical therapya | 905 | (96.4) | 34 | 23–30 |
| Health psychological counseling (group, 60 min.) | 904 | (96.3) | 1 | 1–1 |
| Nutrition counseling | 901 | (96.0) | 2 | 1–3 |
| Psycho-oncology (single, 25 min.) | 877 | (93.4) | 5 | 4–6 |
| Massage/lymph drainage | 855 | (91.1) | 5 | 4–6 |
| Thermotherapy | 791 | (84.2) | 6 | 4–7 |
| Hydrogymnastics | 445 | (47.4) | 4 | 3–5 |
| Self-help training | 412 | (43.9) | 3 | 2–3 |
| Creativity training | 403 | (42.9) | 5 | 3–6 |
| Electrotherapy | 383 | (40.8) | 6 | 4–8 |
| Social counseling | 330 | (35.1) | 1 | 1–1 |
| Biofeedback/relaxation exercise | 141 | (15.0) | 3 | 3–4 |
| Ultrasonic therapy | 37 | (3.9) | 4 | 3–6 |
n number of patients that received specific treatment at least once
aclustered category, including physiotherapy, gymnastics, back exercises, weight training
IQR interquartile range
Fig. 1Flow chart showing inclusion and exclusion of patients in the study
Patient characteristics
| Characteristics | Total sample | |
|---|---|---|
| Mean age (years± SD) | 58.6 (11.9), range:19–88 | |
|
| ||
| Women (%) | 562 | (59.9) |
| Men (%) | 377 | (40.1) |
|
| ||
| Breast cancer | 277 | (29.5) |
| Hemato-oncological malignancy | 99 | (10.5) |
| Colorectal cancer | 94 | (10.0) |
| Head and neck cancer | 62 | (6.6) |
| Prostate cancer (including penis and testes) | 57 | (6.1) |
| Gastric cancer (including esophagus) | 52 | (5.5) |
| Gynecological cancer | 44 | (4.7) |
| Lung cancer | 43 | (4.6) |
| Pancreatic cancer (including liver and gall bladder) | 34 | (3.6) |
| Urinary organs | 34 | (3.6) |
| Brain cancer | 14 | (1.5) |
| Others | 68 | (7.2) |
| Missing data | 61 | (6.5) |
|
| ||
| Mean (SD) | 11.9 | 7.2 |
|
| ||
| Yes | 204 | (21.7) |
| No | 726 | (77.3) |
| Missing | 9 | (1.0) |
|
| ||
| Yes | 453 | (48.2) |
| No | 477 | (50.8) |
| Missing | 9 | (1.0) |
|
| ||
| Sexual psychology | 49 | (10.8) |
| Existential analysis | 130 | (28.7) |
| Biofeedback | 99 | (21.9) |
| No preference | 127 | (28.0) |
| Missing | 48 | (10.6) |
QLQ-C30 and HADS mean values at T0 and T1, effect sizes and reference values (general population)
| Study sample | Reference value | |||||
|---|---|---|---|---|---|---|
| T0 | T1 | Mean difference | ||||
| Mean (SD) | Mean (SD) | Mean (SD) | (T1-T0) | ES |
| |
|
| ||||||
| Anxiety | 6.1 (3.9)* | 4.2 (3.3)* | 4.7 (3.5) |
| 0.49 | <0.001 |
| Depression | 5.6 (4.0)* | 3.4 (3.2)* | 4.8 (4.0) |
| 0.56 | <0.001 |
|
| ||||||
| Physical functioning | 72.3 (21.0)* | 79.8 (19.6)* | 92.2 (15.1) |
| 0.36 | <0.001 |
| Role functioning | 58.0 (31.0)* | 73.0 (26.4)* | 90.4 (20.2) |
| 0.48 | <0.001 |
| Social functioning | 58.8 (30.7)* | 75.9 (25.8)* | 93.4 (17.2) |
| 0.56 | <0.001 |
| Emotional functioning | 58.7 (25.6)* | 78.7 (21.3)* | 83.5 (19.7) |
| 0.78 | <0.001 |
| Cognitive functioning | 72.8 (27.3)* | 78.6 (23.8)* | 93.5 (14.5) |
| 0.21 | <0.001 |
|
| 58.6 (20.3)* | 74.2 (17.6)* | 75.0 (19.6) |
| 0.76 | <0.001 |
|
| ||||||
| Fatigue | 53.0 (26.5)* | 35.8 (23.5)* | 15.5 (21.6) |
| 0.65 | <0.001 |
| Nausea/vomiting | 13.4 (22.4)* | 7.1 (17.2)* | 2.2 (8.9) |
| 0.28 | 0.17 |
| Pain | 40.2 (29.3)* | 27.5 (26.4)* | 16.7 (24.2) |
| 0.43 | <0.001 |
| Dyspnea | 33.8 (32.7)* | 29.3 (27.5)* | 7.5 (19.3) | 4.5 | 0.13 | 0.04 |
| Insomnia | 46.3 (33.9)* | 36.7 (32.3)* | 12.4 (23.3) |
| 0.28 | <0.001 |
| Appetite loss | 26.2 (33.2)* | 14.2 (26.2)* | 3.8 (13.3) |
| 0.36 | <0.001 |
| Constipation | 20.7 (31.3)* | 11.5 (24.2)* | 2.2 (10.3) |
| 0.29 | <0.001 |
| Diarrhea | 17.2 (27.7)* | 11.5 (22.8)* | 2.5 (11.6) |
| 0.21 | <0.001 |
| Financial difficulties | 30.0 (34.0)* | 20.7 (29.8)* | 4.8 (16.6) |
| 0.27 | 0.001 |
Difference = absolute value; clinical meaningful changes [24, 25] in bold type
ES effect size
*Significant difference (p < 0.05) to reference values
HADS anxiety (HADS-A) and depression (HADS-D) severity pretreatment and posttreatment with χ2-values
| T0 | T1 | ||||
|---|---|---|---|---|---|
|
| (%) |
| % |
| |
|
| |||||
| Non-cases (≤7) | 624 | (66.8) | 790 | (84.1) | <0.001 |
| Doubtful cases (8–10) | 178 | (19.1) | 108 | (11.5) | |
| Clinical cases (≥11) | 132 | (14.1) | 38 | (4.0) | |
|
| |||||
| Non-cases (≤7) | 648 | (69.3) | 837 | (89.5) | <0.001 |
| Doubtful cases (8–10) | 158 | (16.9) | 63 | (6.7) | |
| Clinical cases (≥11) | 129 | (13.8) | 35 | (3.7) | |
Fig. 2Mean QLQ-C30 values before and after rehabilitation (with 95% confidence intervals) and mean values for the general population. a QLQ-C30 functioning scales, b QLQ-C30 symptom scales